Skip to main content
OpenTrials
Completed

NCT Number: NCT01542138

Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation

Axillary hyperpigmentation is a frequent consultation in dark skin populations although its exact prevalency is unknown. Currently, there are not studies about physiopathology and treatment for this entity. The objective is to evaluate the depigmenting effect of topical 4% niacinamide versus 0.05% desonide in axillary hyperpigmentation.

At least 30 axillas with hyperpigmentation in individuals of phototype III-V, aged 18-50 years are going to be randomly assigned to receive niacinamide, desonide or placebo daily. No hygienic habits will not be modified. Volunteers will be evaluated at baseline and for 9 weeks, by means of histological, histochemical and immunohistochemistry analysis, as well as Transepidermal Water Loss (TEWL), colorimetry, clinically and by photography control.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Dermatology Department. Hospital Central "Dr. Ignacio Morones Prieto"

San Luis Potosí City, San Luis Potosí, 78210, Mexico

About this study

Axillary hyperpigmentation is frequent in dark skin population, is possible a type of postinflammatory hyperpigmentation present in phototypes IV to VI. Previous reports have described increased intensity of Masson-Fontana, anti-tyrosinase and/or anti-TRP1 staining, indicative of melanocyte stimulation and increased melanin production, but the exact mechanism is unknown. The hair plucking, the rubbing of clothes on skin and physical stimulation from washing and drying the underarm are factors implicated. The objective of our study is evaluate the depigmenting effect of topical niacinamide versus desonide in axillary hyperpigmentation through the histochemistry and immunohistochemistry staining.

The study population will include at least 30 axillas with hyperpigmentation in a population with phototype III-V and aged 18-50 years old. Informed consent will be obtained from the patients, under approval by the local ethical committee (Institutional Review Board). The patients are going to be randomly assigned to receive 4% niacinamide, 0.05% desonide or placebo daily once at night. None hygienic habit is going to be modified. Volunteers will be evaluated at baseline and 9 weeks later, with histochemical and immunohistochemical analysis (biopsies), colorimetric value axis L*, a*, b* (Chromameter CR-300, Minolta, Osaka, Japan), Transepidermal Water Loss (TEWL) by means of an evaporimeter (Dermalab, Cortex Technology, Denmark), clinical assessment and photography control.

Statistical analysis was performed using t student, the level of significance was set at 5%. And clinical evaluation will be analysed by means of chi square test.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women over 18 years old
  • Healthy
  • Clinical diagnosis of axillar hyperpigmentation

Exclusion criteria

  • Pregnancy or lactation
  • Obesity
  • Endocrinological diseases
  • Mental diseases
  • Treatment for axillar hyperpigmentation in the last 2 months

Treatment and study plan

Desonide

Drug

Once-a-day applying on axillar hyperpigmentation for 9 weeks

Other names: 0.05% Desowen cream, Galderma, France.

Niacinamide

Drug

Once-a-day applying on axillar hyperpigmentation for 9 weeks

Other names: Nicotinamide, nicomide

Placebo

Drug

Humectant placebo cream

Other names: vanicream, cetaphil

Primary outcomes

  1. Pigmentation

    Time frame: 9 weeks

    Quantification of melanin content in histologic sections by Fontana-Masson stain

Secondary outcomes

  1. Inflammation

    Time frame: 9 weeks

    Quantification of inflammatory infiltrate in skin biopsies by histologic lymphocites infiltrate and immunohistochemistry stain anti-CD1

  2. Trauma

    Time frame: 9 weeks

    To detect trauma we measure damage in Membrane Basal by anti-collagen IV immunohistochemistry stain

  3. Change in transepidermal water loss in hyperpigmented lesion

    Time frame: 9 weeks

    Quantification of water loss measured by a evaporimeter in grams per squared meter per hour. Is an indirect measure of inflammation.

  4. Investigator's Depigmentation Improvement

    Time frame: 9 weeks

    Clinical improvement is assessed by means of digital photographic registration (frontal, right, and left views). Two independent observers clinically graded the global improvement as poor (0-25%), mild (26-50%), good (51-75%), and excellent (>75%).

Sponsors and collaborators

Lead sponsor

Universidad Autonoma de San Luis Potosí

Other

Collaborators

  • Hospital Central "Dr. Ignacio Morones Prieto"

Registry information

Official study title

A Double Blind, Randomized Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Mar 2, 2012
Registry last updated
Nov 29, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.